MA34952B1 - Combinaisons comprenant du macitentan pour le traitement d'un glioblastome multiforme - Google Patents
Combinaisons comprenant du macitentan pour le traitement d'un glioblastome multiformeInfo
- Publication number
- MA34952B1 MA34952B1 MA36217A MA36217A MA34952B1 MA 34952 B1 MA34952 B1 MA 34952B1 MA 36217 A MA36217 A MA 36217A MA 36217 A MA36217 A MA 36217A MA 34952 B1 MA34952 B1 MA 34952B1
- Authority
- MA
- Morocco
- Prior art keywords
- macitentan
- treatment
- combinations
- glioblastoma
- radiotherapy
- Prior art date
Links
- 208000005017 glioblastoma Diseases 0.000 title abstract 2
- JGCMEBMXRHSZKX-UHFFFAOYSA-N macitentan Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)NCCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 JGCMEBMXRHSZKX-UHFFFAOYSA-N 0.000 title abstract 2
- 229960001039 macitentan Drugs 0.000 title abstract 2
- 231100000433 cytotoxic Toxicity 0.000 abstract 2
- 230000001472 cytotoxic effect Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000001959 radiotherapy Methods 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 208000032612 Glial tumor Diseases 0.000 abstract 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 abstract 1
- 206010018338 Glioma Diseases 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 229960004964 temozolomide Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2011050494 | 2011-02-04 | ||
| PCT/IB2012/050513 WO2012104822A1 (en) | 2011-02-04 | 2012-02-03 | Combinations comprising macitentan for the treatment of glioblastoma multiforme |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA34952B1 true MA34952B1 (fr) | 2014-03-01 |
Family
ID=45787254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA36217A MA34952B1 (fr) | 2011-02-04 | 2012-02-03 | Combinaisons comprenant du macitentan pour le traitement d'un glioblastome multiforme |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20130310407A1 (OSRAM) |
| EP (2) | EP2965757A1 (OSRAM) |
| JP (2) | JP5642892B2 (OSRAM) |
| KR (1) | KR101563069B1 (OSRAM) |
| CN (1) | CN103327975A (OSRAM) |
| AR (1) | AR085132A1 (OSRAM) |
| AU (1) | AU2012213036A1 (OSRAM) |
| BR (1) | BR112013019680A2 (OSRAM) |
| CA (1) | CA2823994A1 (OSRAM) |
| CL (1) | CL2013002193A1 (OSRAM) |
| CO (1) | CO6761366A2 (OSRAM) |
| EA (1) | EA201391131A1 (OSRAM) |
| IL (1) | IL227747A0 (OSRAM) |
| MA (1) | MA34952B1 (OSRAM) |
| MX (1) | MX2013008798A (OSRAM) |
| PH (1) | PH12013501461A1 (OSRAM) |
| SG (1) | SG192600A1 (OSRAM) |
| TN (1) | TN2013000333A1 (OSRAM) |
| TW (1) | TW201309298A (OSRAM) |
| WO (1) | WO2012104822A1 (OSRAM) |
| ZA (1) | ZA201306613B (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101313395B1 (ko) | 2005-09-12 | 2013-10-02 | 액테리온 파마슈티칼 리미티드 | 피리미딘-설파마이드를 함유하는 안정한 제약학적 조성물 |
| ES2543280T3 (es) | 2009-08-10 | 2015-08-17 | Board Of Regents, The University Of Texas System | Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico |
| CN103397308A (zh) * | 2013-08-01 | 2013-11-20 | 光垒光电科技（上海）有限公司 | 用于mocvd设备的喷淋头 |
| TWI559928B (en) * | 2014-08-20 | 2016-12-01 | Academia Sinica | Methods for enhancing permeability to blood-brain barrier and uses thereof |
| KR101701619B1 (ko) | 2015-06-26 | 2017-02-01 | 건양대학교산학협력단 | 뇌교종 세포 치료를 위한 테모졸로마이드와 비타민 d가 포함된 조성물 |
| KR102574253B1 (ko) | 2020-12-15 | 2023-09-07 | 주식회사 시선테라퓨틱스 | 펩티드 핵산 복합체를 유효성분으로 함유하는 교모세포종 예방 또는 치료용 조성물 |
| CN115317604B (zh) * | 2022-08-11 | 2023-09-22 | 南京脑科医院 | 一种靶向胶质瘤的共载放疗增敏阳离子纳米制剂及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100819668B1 (ko) | 2000-12-18 | 2008-04-04 | 액테리온 파마슈티칼 리미티드 | 신규한 피리미딘-설퍼아마이드 |
| KR101313395B1 (ko) | 2005-09-12 | 2013-10-02 | 액테리온 파마슈티칼 리미티드 | 피리미딘-설파마이드를 함유하는 안정한 제약학적 조성물 |
| WO2008111092A1 (en) * | 2007-03-09 | 2008-09-18 | Fresenius Kabi Oncology Limited | Crystalline temozolomide monohydrate and process for preparation thereof |
| KR20100132489A (ko) | 2008-02-20 | 2010-12-17 | 액테리온 파마슈티칼 리미티드 | 난소암을 치료하기 위하여 파클리탁셀을 포함하는 조합 |
| ES2543280T3 (es) * | 2009-08-10 | 2015-08-17 | Board Of Regents, The University Of Texas System | Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico |
-
2012
- 2012-02-03 TW TW101103560A patent/TW201309298A/zh unknown
- 2012-02-03 CA CA2823994A patent/CA2823994A1/en not_active Abandoned
- 2012-02-03 AU AU2012213036A patent/AU2012213036A1/en not_active Abandoned
- 2012-02-03 US US13/983,383 patent/US20130310407A1/en not_active Abandoned
- 2012-02-03 EA EA201391131A patent/EA201391131A1/ru unknown
- 2012-02-03 BR BR112013019680A patent/BR112013019680A2/pt not_active IP Right Cessation
- 2012-02-03 WO PCT/IB2012/050513 patent/WO2012104822A1/en not_active Ceased
- 2012-02-03 KR KR1020137023170A patent/KR101563069B1/ko not_active Expired - Fee Related
- 2012-02-03 MX MX2013008798A patent/MX2013008798A/es active IP Right Grant
- 2012-02-03 PH PH1/2013/501461A patent/PH12013501461A1/en unknown
- 2012-02-03 CN CN2012800059659A patent/CN103327975A/zh active Pending
- 2012-02-03 EP EP15178064.0A patent/EP2965757A1/en not_active Withdrawn
- 2012-02-03 SG SG2013058979A patent/SG192600A1/en unknown
- 2012-02-03 EP EP12706925.0A patent/EP2670405B1/en not_active Not-in-force
- 2012-02-03 MA MA36217A patent/MA34952B1/fr unknown
- 2012-02-03 JP JP2013552318A patent/JP5642892B2/ja not_active Expired - Fee Related
- 2012-02-03 AR ARP120100357A patent/AR085132A1/es unknown
-
2013
- 2013-07-10 CO CO13163973A patent/CO6761366A2/es not_active Application Discontinuation
- 2013-07-31 CL CL2013002193A patent/CL2013002193A1/es unknown
- 2013-08-01 TN TNP2013000333A patent/TN2013000333A1/fr unknown
- 2013-08-01 IL IL227747A patent/IL227747A0/en unknown
- 2013-09-03 ZA ZA2013/06613A patent/ZA201306613B/en unknown
-
2014
- 2014-10-28 JP JP2014219218A patent/JP2015057409A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR085132A1 (es) | 2013-09-11 |
| CA2823994A1 (en) | 2012-08-09 |
| CO6761366A2 (es) | 2013-09-30 |
| IL227747A0 (en) | 2013-09-30 |
| NZ615005A (en) | 2015-10-30 |
| WO2012104822A1 (en) | 2012-08-09 |
| MX2013008798A (es) | 2013-10-17 |
| EP2670405A1 (en) | 2013-12-11 |
| TN2013000333A1 (en) | 2015-01-20 |
| US20130310407A1 (en) | 2013-11-21 |
| TW201309298A (zh) | 2013-03-01 |
| SG192600A1 (en) | 2013-09-30 |
| KR101563069B1 (ko) | 2015-10-23 |
| BR112013019680A2 (pt) | 2016-10-11 |
| EP2670405B1 (en) | 2015-09-02 |
| CN103327975A (zh) | 2013-09-25 |
| CL2013002193A1 (es) | 2014-05-09 |
| ZA201306613B (en) | 2015-04-29 |
| KR20130118981A (ko) | 2013-10-30 |
| AU2012213036A1 (en) | 2013-09-19 |
| EP2965757A1 (en) | 2016-01-13 |
| EA201391131A1 (ru) | 2013-12-30 |
| JP2014504636A (ja) | 2014-02-24 |
| JP5642892B2 (ja) | 2014-12-17 |
| PH12013501461A1 (en) | 2019-03-22 |
| JP2015057409A (ja) | 2015-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA34952B1 (fr) | Combinaisons comprenant du macitentan pour le traitement d'un glioblastome multiforme | |
| MA35210B1 (fr) | Polythérapie comportant un inhibiteur de cdk4/6 et un inhibiteur de pi3k à utiliser dans le traitement du cancer | |
| EP2868667A4 (en) | THERAPEUTIC FOR ANEMIA, INCLUDING NICE ENAMA AND CANCER-INDUCED ANEMIA WITH ANTI-BMP9 ANTIBODY AS ACTIVE AGENT | |
| MA39094A1 (fr) | Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers | |
| MX2018004832A (es) | Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer. | |
| CL2008001374A1 (es) | Compuestos derivados de pirazolo pirimidinas, inhibidores de pde9; composicion farmaceutica que comprende a dichos compuetos; utiles en el tratamiento de un trastorno neurodegenerativo y cognitivo tal como la enfermedad de alzheimer y esquizofrenia. | |
| UA112434C2 (uk) | Антигензв'язувальний білок, який специфічно зв'язується з всма | |
| EP3393475C0 (en) | CIFORADENT ALONE OR IN COMBINATION WITH ATEZOLIZUMAB FOR USE IN THE TREATMENT OF CANCER | |
| MX391101B (es) | Complejo de agentes quimioterapéuticos en microburbujas para terapia sonodinámica. | |
| MA38814B2 (fr) | Agoniste gitr et antagoniste pd-1 pour leurs utilisations dans le traitement de troubles proliferatifs | |
| EP2154971A4 (en) | SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | |
| GB201204263D0 (en) | Giloma treatment | |
| EA201591403A1 (ru) | Спиролактамные модуляторы рецептора nmda и их применение | |
| EP2889032A4 (en) | COMPOSITION FOR PREVENTING OR TREATING NURSE DISEASES WITH A PYRAZOLE DERIVATIVE | |
| MA47356B1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
| UA113849C2 (xx) | Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу | |
| CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
| EP2671524A4 (en) | CATHETER FOR TREATING A REFRIGERATOR, CATHETER GUIDANCE AND CATHETER UNIT FOR TREATING A REFURBISHERY | |
| MA39146A1 (fr) | Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma | |
| EP2208498A4 (en) | PHARMACEUTICAL COMPOSITION OF A COMBINATION OF VARIOUS VENOTONIC AND VASO-PROTECTIVE AGENTS FOR THE TREATMENT OF CHRONIC VEININ INSUFFICIENCY | |
| MA38253B1 (fr) | Compositions comprenant de la vortioxétine et du donépézil | |
| MA35281B1 (fr) | Dosage et administration d'anticorps anti-erbb3 en combinaison avec le paclitaxel pour le traitement de cancers gynécologiques | |
| MA34827B1 (fr) | Protéine hybrides robo1-fc à utiliser dans traitement d'hépatocarcinomes | |
| MA44700A (fr) | Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer | |
| AU2013208104A8 (en) | Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof |